ReviewMolecular neurobiology2013
Glaucoma: an extension of various chronic neurodegenerative disorders.
Review in Molecular neurobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- A study exploring the causal relationship between glaucoma and anxiety disorders.Frontiers in medicine · 2024Article
- Review
- Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.Pharmaceutics · 2023Review
- Glaucoma and cognitive function trajectories in a population-based study: Findings from the health and retirement study.Journal of the American Geriatrics Society · 2022Article
- Advanced Diffusion MRI of the Visual System in Glaucoma: From Experimental Animal Models to Humans.Biology · 2022Review
- Shared genetic architecture between the two neurodegenerative diseases: Alzheimer's disease and glaucoma.Frontiers in aging neuroscience · 2022Article
- The effect of anxiety and depression on progression of glaucoma.Scientific reports · 2021Article
- Resveratrol Protects Optic Nerve Head Astrocytes from Oxidative Stress-Induced Cell Death by Preventing Caspase-3 Activation, Tau Dephosphorylation at SerCellular and molecular neurobiology · 2020Article
- Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma.Scientific reports · 2020Article
- Linking neural and clinical measures of glaucoma with diffusion magnetic resonance imaging (dMRI).PloS one · 2019Article
- Research progress on human genes involved in the pathogenesis of glaucoma (Review).Molecular medicine reports · 2018Review
- Glaucoma and Alzheimer Disease: One Age-Related Neurodegenerative Disease of the Brain.Current neuropharmacology · 2018Review
- The Role of Long Noncoding RNAs in Neurodegenerative Diseases.Molecular neurobiology · 2017Review
- Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma.Frontiers in neuroscience · 2017Article
- Early changes of brain connectivity in primary open angle glaucoma.Human brain mapping · 2016Article
- Longitudinal Analysis of Serum Autoantibody-Reactivities in Patients with Primary Open Angle Glaucoma and Optic Disc Hemorrhage.PloS one · 2016Article
- Perceptual Learning for Rehabilitation in Traumatic Optic Neuropathy.Neuro-ophthalmology (Aeolus Press) · 2014Article
- Autophagy in retinal ganglion cells in a rhesus monkey chronic hypertensive glaucoma model.PloS one · 2013Article
- Ocular and Systemic Factors Associated with Glaucoma.Journal of current glaucoma practiceReview
- Psychological Distress Associated With Suicidal Ideation Among Glaucoma Patients Attending at Tertiary Eye Care Clinic, Gondar, Ethiopia.SAGE open nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eyes are the window of the brain; various pathologies of the eyes can be explained on the basis of neurological disorders and vice versa. Today, our only approach for the management of glaucoma is intraocular pressure (IOP) reduction, whether by pharmacological or surgical methods. Available methods may effectively control IOP but fall short of stopping the progression of glaucoma. IOP is just one of the risk factors our therapy addresses, so we need to work towards shifting our approach towards addressing other factors involved in the etiopathogenesis of the disease. Pathogenesis of glaucoma at molecular level can be compared with that of common neurodegenerative diseases like Alzheimer's and Parkinsonism. Targets for therapeutic intervention in chronic neurodegenerative diseases and glaucoma include apoptosis, axonal transport, free radical damage, role of polyunsaturated fatty acids, chaperones, gene regulation, etc. p38MAPK is a common pathway involved in all the neurodegenerative disease and glaucoma as well, and more research in this direction can be really beneficial for the development of novel diagnostic and therapeutic measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.